Misplaced Pages

Homotaurine: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 21:11, 9 March 2016 editJytdog (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers187,951 edits this is a 30 year old primary source. about guinea pigs not rats in any case← Previous edit Revision as of 21:15, 9 March 2016 edit undoFonsy74 (talk | contribs)77 editsNo edit summaryNext edit →
Line 50: Line 50:


Homotaurine has also been investigated as a potential treatment for ].<ref>{{cite journal | pmid= 19536424| year= 2009| author1= Gauthier| first1= S| title= Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study| journal= The journal of nutrition, health & aging| volume= 13| issue= 6| pages= 550–7| last2= Aisen| first2= P. S.| last3= Ferris| first3= S. H.| last4= Saumier| first4= D| last5= Duong| first5= A| last6= Haine| first6= D| last7= Garceau| first7= D| last8= Suhy| first8= J| last9= Oh| first9= J| last10= Lau| first10= W| last11= Sampalis| first11= J}}</ref> It binds to soluble ] and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain.<ref>{{cite journal |author=Aisen PS, Gauthier S, Vellas B |title=Alzhemed: a potential treatment for Alzheimer's disease |journal=Curr Alzheimer Res |volume=4 |issue=4 |pages=473–8 |year=2007 |pmid=17908052 |doi=10.2174/156720507781788882 |displayauthors=etal }}</ref> However, clinical trials failed to show improvement compared to placebo.<ref>{{cite web |title = Tramiprosate Falls Short in Phase III Alzheimer's Trial | date = November 1, 2007 | url = http://www.clinicalpsychiatrynews.com/search/search-single-view/tramiprosate-falls-short-in-phase-iii-alzheimer-s-trial-unusually-large-placebo-effect-could-be-a-recurring-problem-in-studies-that-allow-concomitant-medications/33faa3a863.html | publisher = Clinical Psychiatry News}}</ref><ref name=alzhemed-clintrials>{{cite web|url=http://www.alzforum.org/drg/drc/detail.asp?id=84|title=Drugs In Clinical Trials : Alzhemed|publisher=Alzheimer Research Forum|accessdate=1 October 2011}}</ref><ref name=alzhemed-nationalpost>{{cite news|url=http://www.canada.com/nationalpost/financialpost/investing/story.html?id=1182469f-afb5-41f6-87d6-a2219c489800|title=Analysts Skeptical Of Neurochem's Efforts To Salvage Value From Alzhemed|accessdate=1 October 2011|newspaper=Canada National Post|date=November 13, 2007}}</ref> Homotaurine has also been investigated as a potential treatment for ].<ref>{{cite journal | pmid= 19536424| year= 2009| author1= Gauthier| first1= S| title= Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study| journal= The journal of nutrition, health & aging| volume= 13| issue= 6| pages= 550–7| last2= Aisen| first2= P. S.| last3= Ferris| first3= S. H.| last4= Saumier| first4= D| last5= Duong| first5= A| last6= Haine| first6= D| last7= Garceau| first7= D| last8= Suhy| first8= J| last9= Oh| first9= J| last10= Lau| first10= W| last11= Sampalis| first11= J}}</ref> It binds to soluble ] and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain.<ref>{{cite journal |author=Aisen PS, Gauthier S, Vellas B |title=Alzhemed: a potential treatment for Alzheimer's disease |journal=Curr Alzheimer Res |volume=4 |issue=4 |pages=473–8 |year=2007 |pmid=17908052 |doi=10.2174/156720507781788882 |displayauthors=etal }}</ref> However, clinical trials failed to show improvement compared to placebo.<ref>{{cite web |title = Tramiprosate Falls Short in Phase III Alzheimer's Trial | date = November 1, 2007 | url = http://www.clinicalpsychiatrynews.com/search/search-single-view/tramiprosate-falls-short-in-phase-iii-alzheimer-s-trial-unusually-large-placebo-effect-could-be-a-recurring-problem-in-studies-that-allow-concomitant-medications/33faa3a863.html | publisher = Clinical Psychiatry News}}</ref><ref name=alzhemed-clintrials>{{cite web|url=http://www.alzforum.org/drg/drc/detail.asp?id=84|title=Drugs In Clinical Trials : Alzhemed|publisher=Alzheimer Research Forum|accessdate=1 October 2011}}</ref><ref name=alzhemed-nationalpost>{{cite news|url=http://www.canada.com/nationalpost/financialpost/investing/story.html?id=1182469f-afb5-41f6-87d6-a2219c489800|title=Analysts Skeptical Of Neurochem's Efforts To Salvage Value From Alzhemed|accessdate=1 October 2011|newspaper=Canada National Post|date=November 13, 2007}}</ref>


It is a GABAb receptor antagonist <ref>{{cite journal |author=Giotti A, Luzzi S, Spagnesi S, Zilletti L. |title=Homotaurine: a GABAB antagonist in guinea-pig ileum. |pmid=6652358 }}</ref> and reversed the catatonia induced by baclofen in rats. <ref>{{cite journal |author=Mehta AK1, Ticku MK. |title=Baclofen induces catatonia in rats. |pmid=2823166 }}</ref>
Moreover, Homotaurine suppress ethanol-stimulated dopamine release, ethanol intake and preference in rats similar to acamprosate (Acetylated homotaurine analogue) <ref>{{cite journal |author=Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. |title=Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release. |pmid=11864639 }}</ref>.


Homotaurine is a ] at neutral ]. Homotaurine is a ] at neutral ].

Revision as of 21:15, 9 March 2016

Homotaurine
Skeletal formula
Ball-and-stick model
Names
IUPAC name 3-Aminopropane-1-sulfonic acid
Other names Tramiprosate; Alzhemed; 3-APS
Identifiers
CAS Number
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.020.889 Edit this at Wikidata
KEGG
PubChem CID
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)Key: SNKZJIOFVMKAOJ-UHFFFAOYSA-N
  • InChI=1/C3H9NO3S/c4-2-1-3-8(5,6)7/h1-4H2,(H,5,6,7)Key: SNKZJIOFVMKAOJ-UHFFFAOYAT
SMILES
  • O=S(=O)(O)CCCN
Properties
Chemical formula C3H9NO3S
Molar mass 139.17 g·mol
Melting point 293 °C (559 °F; 566 K) (decomposition)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Homotaurine (3-amino-1-propanesulfonic acid (3-APS) or tramiprosate (INN)) is a synthetic organic compound. It is analogous to taurine, but with an extra carbon in its chain. Because of its similarity in structure to the neurotransmitter gamma-aminobutyric acid (GABA), it has GABAergic effects and may be useful as an anticonvulsant.

Homotaurine has also been investigated as a potential treatment for Alzheimer's disease. It binds to soluble amyloid beta and inhibits the formation of neurotoxic aggregates that lead to amyloid plaque deposition in the brain. However, clinical trials failed to show improvement compared to placebo.


It is a GABAb receptor antagonist and reversed the catatonia induced by baclofen in rats. Moreover, Homotaurine suppress ethanol-stimulated dopamine release, ethanol intake and preference in rats similar to acamprosate (Acetylated homotaurine analogue) .

Homotaurine is a zwitterion at neutral pH.

Skeletal formulaBall-and-stick modelThe zwitterionic form of homotaurine

See also

References

  1. Homotaurine at Sigma-Aldrich
  2. Fariello RG, Golden GT, Pisa M; Golden; Pisa (1982). "Homotaurine (3 aminopropanesulfonic acid; 3APS) protects from the convulsant and cytotoxic effect of systemically administered kainic acid". Neurology. 32 (3): 241–5. doi:10.1212/wnl.32.3.241. PMID 7199633.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. Gauthier, S; Aisen, P. S.; Ferris, S. H.; Saumier, D; Duong, A; Haine, D; Garceau, D; Suhy, J; Oh, J; Lau, W; Sampalis, J (2009). "Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study". The journal of nutrition, health & aging. 13 (6): 550–7. PMID 19536424.
  4. Aisen PS, Gauthier S, Vellas B (2007). "Alzhemed: a potential treatment for Alzheimer's disease". Curr Alzheimer Res. 4 (4): 473–8. doi:10.2174/156720507781788882. PMID 17908052. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)CS1 maint: multiple names: authors list (link)
  5. "Tramiprosate Falls Short in Phase III Alzheimer's Trial". Clinical Psychiatry News. November 1, 2007.
  6. "Drugs In Clinical Trials : Alzhemed". Alzheimer Research Forum. Retrieved 1 October 2011.
  7. "Analysts Skeptical Of Neurochem's Efforts To Salvage Value From Alzhemed". Canada National Post. November 13, 2007. Retrieved 1 October 2011.
  8. Giotti A, Luzzi S, Spagnesi S, Zilletti L. "Homotaurine: a GABAB antagonist in guinea-pig ileum". PMID 6652358. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)
  9. Mehta AK1, Ticku MK. "Baclofen induces catatonia in rats". PMID 2823166. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: numeric names: authors list (link)
  10. Olive MF, Nannini MA, Ou CJ, Koenig HN, Hodge CW. "Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release". PMID 11864639. {{cite journal}}: Cite journal requires |journal= (help)CS1 maint: multiple names: authors list (link)


Anticonvulsants (N03)
GABAergics
GABAAR PAMs
GABA-T inhibitors
Others
Channel
modulators
Sodium blockers
Calcium blockers
Potassium openers
Others
CA inhibitors
Others
GABA receptor modulators
Ionotropic
GABAATooltip γ-Aminobutyric acid A receptor
GABAA-ρTooltip γ-Aminobutyric acid A-rho receptor
Metabotropic
GABABTooltip γ-Aminobutyric acid B receptor
See also
Receptor/signaling modulators
GABAA receptor positive modulators
GABA metabolism/transport modulators


Stub icon

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories:
Homotaurine: Difference between revisions Add topic